Novo Holdings nearly doubles earnings as Wegovy swells coffers
Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...
Wegovy sees Novo Holdings double income and returns in 2024
Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...
Fierce Pharma6h
Novo's commercial strategy head hits the exit, prompting a slew of executive team shakeups
Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...
Becker's Hospital Review9d
Novo Nordisk expands access to reduced-cost Wegovy
Novo Nordisk has updated its Wegovy savings program, allowing eligible cash-paying patients to access the drug at retail ...
Why cheaper alternatives to weight-loss drugs like Wegovy, Zepbound will be tougher to get
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The restrictions began because the FDA declared a shortage of tirzepatide, often ...
BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag
Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...
Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® ...
Germany’s SAP Overtakes Wegovy Maker Novo Nordisk as Europe’s Most Valuable Company
The business-software group claimed the top spot as Europe’s largest company by market value, dethroning Wegovy maker Novo ...
Fierce Pharma3d
FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
Barclays cuts Novo Nordisk estimates on lower Wegovy, Ozempic volumes in the U.S.
Barclays has lowered its first-quarter 2025 estimates for Novo Nordisk (CSE:NOVOb) (NYSE:NVO) ahead of its Q1 2025 report, citing weaker-than-expected prescription volumes for key drugs Wegovy and ...
Novo shares on track for biggest monthly fall since 2002, investor worries grow
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...